Nuzenio

Reduce Mace Risk

Reduce Mace Risk news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 10 latest news signals 10 publisher sources 100/100 entity strength

Latest news

Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease - Pharmacy TimesPharmacy Times · Sun, 09 Aug 2026 14:05:20 GMTMACE Risk May Be Reduced with GLP-1 Drug in High-Risk Patients - Inside Precision MedicineInside Precision Medicine · Fri, 07 Aug 2026 00:54:43 GMTCould GLP-1 Drugs Lower Heart Attack Risk? - Technology NetworksTechnology Networks · Wed, 05 Aug 2026 22:47:00 GMTZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients - TCTMD.comTCTMD.com · Mon, 03 Aug 2026 17:05:08 GMTNovo Nordisk’s mAb for MACE risk reduction fails in Phase III trial - Clinical Trials ArenaClinical Trials Arena · Fri, 31 Jul 2026 15:22:14 GMTZiltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial - HCPLiveHCPLive · Fri, 31 Jul 2026 12:42:48 GMTNovo drug trial fail deals setback to bid to expand beyond obesity - ReutersReuters · Fri, 31 Jul 2026 07:00:00 GMTNovo Nordisk's Ziltivekimab Fails to Reduce Cardiovascular Events in Phase 3 ZEUS Trial - BioPharm InternationalBioPharm International · Fri, 31 Jul 2026 07:00:00 GMT

Timeline

Sun, 09 Aug 2026 14:05:20 GMTTirzepatide Cuts MACE Risk in Diabetes With Heart Disease - Pharmacy Times
Fri, 07 Aug 2026 00:54:43 GMTMACE Risk May Be Reduced with GLP-1 Drug in High-Risk Patients - Inside Precision Medicine
Wed, 05 Aug 2026 22:47:00 GMTCould GLP-1 Drugs Lower Heart Attack Risk? - Technology Networks
Mon, 03 Aug 2026 17:05:08 GMTZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients - TCTMD.com
Fri, 31 Jul 2026 15:22:14 GMTNovo Nordisk’s mAb for MACE risk reduction fails in Phase III trial - Clinical Trials Arena
Fri, 31 Jul 2026 12:42:48 GMTZiltivekimab Fails to Reduce MACE Risk in Phase 3 ZEUS Trial - HCPLive

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Reduce Mace Risk.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

10 distinct publisher/source names are currently connected to this entity page.